Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions | Citedby Results | Respiration | Karger Publishers

Skip to Main Content

Skip Nav Destination

Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions

Respiration (2014) 88 (2): 158–161.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Safety of omalizumab in the treatment of moderate-to-severe bronchial asthma

Ksenia O. Shnaider
Maksim L. Maksimov
Boris K. Romanov

Medical Journal of the Russian Federation (2022) 28 (1): 89.

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Corrado Pelaia
Cecilia Calabrese
Rosa Terracciano
Francesco de Blasio
Alessandro Vatrella
Girolamo Pelaia

Therapeutic Advances in Respiratory Disease (2018) 12: 175346661881019.

Intranasal exposure to monoclonal antibody Fab fragments to Japanese cedar pollen Cry j1 suppresses Japanese cedar pollen‐induced allergic rhinitis

S Yoshino
N Mizutani

British Journal of Pharmacology (2016) 173 (10): 1629.

Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report

S Borekci
O Aydin
G Hatemi
B Gemicioglu

International Journal of Immunopathology and Pharmacology (2015) 28 (1): 134.

Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives

Konstantinos Samitas
Vasiliki Delimpoura
Eleftherios Zervas
Mina Gaga

European Respiratory Review (2015) 24 (138): 594.